Edgewater Capital Partners Acquires Haematologic Technologies
October 11, 2019
Edgewater Capital Partners has entered into an agreement to acquire Haematologic Technologies Incorporated, a Vermont-based provider of biologic products, reagents and GMP-compliant assay development and testing services for the biopharmaceutical industry. Edgewater said it will support HTI's next phase of growth and build the company as a premier outsourced services partner for biologics; financial terms were not disclosed.
- Buyers
- Edgewater Capital Partners
- Targets
- Haematologic Technologies Incorporated
- Industry
- Biotechnology
- Location
- Vermont, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Avista Capital Partners Acquires Taconic Biosciences
November 1, 2022
Biotechnology
Avista Capital Partners has acquired Taconic Biosciences from H.I.G. Capital. Taconic, a Rensselaer, New York–based provider of genetically engineered murine research models and related preclinical services, will leverage Avista's healthcare investing expertise to pursue organic growth and strategic acquisitions in the GEMs market.
-
InVita Healthcare Technologies / The Riverside Company Acquire BloodHub
October 6, 2022
Cloud & SaaS
InVita Healthcare Technologies, a portfolio company of The Riverside Company, has acquired BloodHub and folded it into InVita's Blood Management Division. Riverside made the investment as an add-on to its InVita platform to expand InVita's blood- and biologics-focused supply chain and laboratory software capabilities across North America.
-
Edgewater Capital Partners Acquires GL CHEMTEC
August 11, 2022
Pharmaceuticals
Edgewater Capital Partners, a Cleveland-based lower middle-market private equity firm, has acquired GL CHEMTEC, a chemistry-based contract research organization (CRO) headquartered in Oakville, Ontario. Edgewater will support GLC's expansion of API development, scale-up and advanced materials capabilities to accelerate growth across North American pharma and life-sciences customers.
-
Montagu Acquires Majority Stake in HTL Biotechnology
February 28, 2022
Pharmaceuticals
Montagu, a leading private equity firm, has acquired a majority stake in HTL (HTL Biotechnology) from Bridgepoint, with minority shareholders Naxicap and Téthys Invest retaining their holdings. Montagu will support HTL's international expansion, R&D and premium product positioning and has appointed Paul Navarre as Chairman to help drive the company's next growth phase.
-
The Riverside Company Invests in HemaTerra Technologies
April 18, 2019
Cloud & SaaS
The Riverside Company has invested in HemaTerra Technologies, a provider of cloud-based SaaS solutions for blood and plasma collection centers, hospitals and related healthcare organizations. Riverside said it will invest in product development, sales and marketing, and strategic partnerships to scale HemaTerra's offerings and support continued growth.
-
H.I.G. Capital Acquires Taconic Biosciences
February 7, 2019
Healthcare Services
H.I.G. Capital, through an affiliate, has completed the acquisition of Taconic Biosciences, a global provider of genetically engineered research models and related services. The private equity investment will partner with Taconic's management to support geographic expansion, broaden product and service offerings, and accelerate M&A-driven growth.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.